Atorvastatin versus tetrahydrolipstatin in male patients with dyslipidemia

Excerpt:


J. Pharm. Pharmacogn. Res., vol. 12, no. 2, pp. 218-230, Mar-Apr 2024. DOI: https://doi.org/10.56499/jppres23.1741_12.2.218 Review Atorvastatin versus tetrahydrolipstatin in male patients with dyslipidemia: A systematic review and meta-analysis [Atorvastatina frente a tetrahidrolipstatina en pacientes varones con dislipidemia: Una revisión sistemática y meta-análisis] Nur Aini Hasan1,3, Viskasari Pintoko Kalanjati2*, Kusuma Eko Purwantari2, Abdurachman Abdurachman2, Muhammad Miftahussurur4,5 … Continue reading Atorvastatin versus tetrahydrolipstatin in male patients with dyslipidemia

J. Pharm. Pharmacogn. Res., vol. 12, no. 2, pp. 218-230, Mar-Apr 2024.

DOI: https://doi.org/10.56499/jppres23.1741_12.2.218

Review

Atorvastatin versus tetrahydrolipstatin in male patients with dyslipidemia: A systematic review and meta-analysis

[Atorvastatina frente a tetrahidrolipstatina en pacientes varones con dislipidemia: Una revisión sistemática y meta-análisis]

Nur Aini Hasan1,3, Viskasari Pintoko Kalanjati2*, Kusuma Eko Purwantari2, Abdurachman Abdurachman2, Muhammad Miftahussurur4,5

1Master of Basic Medical Sciences in Anatomy and Histology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

2Department of Anatomy, Histology and Pharmacology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

3Department of Anatomy and Histology, Faculty of Medicine, Universitas Muhammadiyah Sidoarjo, Indonesia.

4Helicobacter pylori and Microbiota Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia.

5Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo General Academic Hospital, Universitas Airlangga, Surabaya, Indonesia.

*E-mail: viskasari-p-k@fk.unair.ac.id

Abstract

Context: Atorvastatin is typically used in the treatment of dyslipidemia. However, the interest in using anti-obesity medications such as orlistat has grown rapidly as obesity is one of the variables associated with dyslipidemia.

Aims: To synthesize the findings from previous studies published to date on the potential effects of atorvastatin and tetrahydrolipstatin (orlistat) on the levels of serum LDL.

Methods: A systematic review and meta-analysis of research reports and RCTs about atorvastatin and orlistat on LDL levels from articles published in Medline, PubMed, and Scopus from 2012 to 2022 were conducted using PRISMA and RevMan 5.4 software.

Results: From 9 final included articles, 6 focused on atorvastatin and 3 on orlistat. Five papers on atorvastatin reported a significant decrease in LDL level, whereas only 2 from orlistat papers. There is a significant decrease in LDL level associated with Atorvastatin treatment (p = 0.04, CI = 1.58, 56.81, I2 = 99%), but not with orlistat (p = 0.05, CI = 0.10, 17.69, I2 = 93%).

Conclusions: Here, it is shown that atorvastatin instead of orlistat has a significant effect on decreasing LDL serum levels in dyslipidemia patients.

Keywords: atorvastatin; dyslipidemia; obesity; orlistat; tetrahydrolipstatin.

jppres_pdf_free

Resumen

Contexto: La atorvastatina se utiliza habitualmente en el tratamiento de la dislipidemia. Sin embargo, el interés por utilizar medicamentos contra la obesidad, como el orlistat, ha crecido rápidamente, ya que la obesidad es una de las variables asociadas a la dislipidemia.

Objetivos: Sintetizar los hallazgos de estudios previos publicados hasta la fecha sobre los efectos potenciales de la atorvastatina y la tetrahidrolipstatina (orlistat) en los niveles de LDL sérico.

Métodos: Se realizó una revisión sistemática y un meta-análisis de informes de investigación y ECA sobre atorvastatina y orlistat en los niveles de LDL de artículos publicados en Medline, PubMed y Scopus desde 2012 hasta 2022 utilizando PRISMA y el software RevMan 5.4.

Resultados: De 9 artículos finales incluidos, 6 se centraron en atorvastatina y 3 en orlistat. Cinco artículos sobre atorvastatina informaron de una disminución significativa del nivel de LDL, mientras que sólo 2 de los artículos sobre orlistat. Existe una disminución significativa del nivel de LDL asociada al tratamiento con atorvastatina (p = 0,04; IC = 1,58; 56,81; I2 = 99%), pero no con orlistat (p = 0,05; IC = 0,10; 17,69; I2 = 93%).

Conclusiones: Aquí se demuestra que la atorvastatina en lugar del orlistat tiene un efecto significativo en la disminución de los niveles séricos de LDL en pacientes con dislipidemia.

Palabras Clave: atorvastatina; dislipidemia; obesidad; orlistat; tetrahidrolipstatina.

jppres_pdf_free

 

 
 
Citation Format: Hasan NA, Kalanjati VP, Purwantari KE, Abdurachman A, Mifftahussurur M (2024) Atorvastatin versus tetrahydrolipstatin in male patients with dyslipidemia: A systematic review and meta-analysis. J Pharm Pharmacogn Res 12(2): 218–230. https://doi.org/10.56499/jppres23.1741_12.2.218
References

Agrawal D, Manchanda SC, Sawhney JPS, Kandpal B, Jain R, Mehta A, Mohanty A, Passey R, Makhija A, Sharma MK (2018) To study the effect of high dose atorvastatin 40 mg versus 80 mg in patients with dyslipidemia. Indian Heart J 70: S8–S12. https://doi.org/10.1016/j.ihj.2018.01.034

Alanazi J, Unnisa A, Ahmad S, Itumalla R, Alanazi M, Alharby TN, Anwar S, Younes KM, Hussain T, Hussain A, Elamine BA, Mohamed OA (2022) Significance of orlistat in management of dyslipidemia, systolic blood pressure and body mass index. Eur Rev Med Pharmacol Sci 26: 8326–8332. https://doi.org/10.26355/eurrev_202211_30365

Bénarouche A, Point V, Carrière F, Cavalier JF (2014) Using the reversible inhibition of gastric lipase by orlistat for investigating simultaneously lipase adsorption and substrate hydrolysis at the lipid-water interface. Biochimie 101: 221–231. https://doi.org/10.1016/j.biochi.2014.01.019

Bencharif K, Hoareau L, Murumalla RK, Tarnus E, Tallet F, Clerc RG, Gardes C, Cesari M, Roche R (2010) Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes. Lipids Health Dis 9: 75. https://doi.org/10.1186/1476-511X-9-75

Berkhout SW, Haaf JM, Gronau QF, Heck DW, Wagenmakers EJ (2023) A tutorial on Bayesian model-averaged meta-analysis in JASP. Behav Res Methods. https://doi.org/10.3758/s13428-023-02093-6

Bessesen DH, Van Gaal LF (2018) Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol 6(3): 237–248. https://doi.org/10.1016/S2213-8587(17)30236-X

Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA; DESCARTES Investigators (2014) A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 370: 1809–1819. https://doi.org/10.1056/nejmoa1316222

Dettori JR, Norvell DC, Chapman JR (2022) Fixed-effect vs random-effects models for meta-analysis: 3 points to consider. Global Spine J 12: 1624-1626. https://doi.org/10.1177/21925682221110527

Dias S, Paredes S, Ribeiro L (2018) Drugs involved in dyslipidemia and obesity treatment: Focus on adipose tissue. Int J Endocrinol 2018: 2637418. https://doi.org/10.1155/2018/2637418

Fairuz JJ, Sari DR, Soelistijo SA (2021) Correlation between metabolic syndrome and serum uric acid in the office workers of a BUMN company in Surabaya, Indonesia. Biomorphol J 31: 11–17. https://doi.org/10.20473/mbiom.v31i1.2021.11-17

Fujioka K (2015) Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab 17: 1021–1032. https://doi.org/10.1111/dom.12502

Grundy SM, Arai H, Barter P, Bersot TP, Betteridge DJ, Carmena R, Cuevas A, Davidson MH, Genest J, Kesäniemi YA, Sadikot S, Santos RD, Susekov AV, Sy RG, LaleTokgözoglu S, Watts GF, Zhao D (2014) An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia - Full report. J Clin Lipidol 8: 29–60. https://doi.org/10.1016/j.jacl.2013.12.005

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73: 3168–3209. https://doi.org/10.1016/j.jacc.2018.11.002

Heck AM, Yanovski JA, Calis KA (2000) Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 20: 270–279. https://doi.org/10.1592/phco.20.4.270.34882

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors) (2019) Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons. https://doi.org/10.1002/9781119536604

Hing Ling PK, Civeira F, Dan AG, Hanson ME, Massaad R, De Tilleghem Cle B, Milardo C, Triscari J (2012) Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: A randomized, double-blind, active-controlled, multicenter study. Lipids Health Dis 11: 18. https://doi.org/10.1186/1476-511X-11-18

Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV, Underberg JA; NLA Expert Panel (2015) National lipid association recommendations for patient-centered management of dyslipidemia: Part 2. J Clin Lipidol 9: S1–S122.e1. https://doi.org/10.1016/j.jacl.2015.09.002

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1–12. https://doi.org/10.1016/0197-2456(95)00134-4

Jin J, Cheng R, Ren Y, Shen X, Wang J, Xue Y, Zhang H, Jia X, Li T, He F, Tian H (2021) Distinctive gut microbiota in patients with overweight and obesity with dyslipidemia and its responses to long-term orlistat and ezetimibe intervention: A randomized controlled open-label trial. Front Pharmacol 12: 732541. https://doi.org/10.3389/fphar.2021.732541

Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, Lévy PA, Gagnadoux F, Pepin JL (2014) Response to statin therapy in obstructive sleep apnea syndrome: A multicenter randomized controlled trial. Mediators Inflamm 2014: 423120. https://doi.org/10.1155/2014/423120

Juandi D, Tamur M (2021) Problem-based learning for mathematical critical thinking skills: A meta-analysis. J Hunan Univ Nat Sci 48: 133–144.

Jung UJ, Choi MS (2014) Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and non-alcoholic fatty liver disease. Int J Mol Sci 15: 6184–6223. https://doi.org/10.3390/ijms15046184

Kalanjati VP, Oktariza RT, Suwito BE, Pradana KA, Rahmawan D, Abdurachman (2021) Cardiovascular disease risk factors and anthropometry features among seemingly healthy young adults. Int J Publ Health Sci 10: 77–82. https://doi.org/10.11591/ijphs.v10i1.20554

Kotseva K, De Bacquer D, Jennings C, Gyberg V, De Backer G, Rydén L, Amouyel P, Bruthans J, Cifkova R, Deckers JW, De Sutter J, Fraz Z, Graham I, Keber I, Lehto S, Moore D, Pajak A, Wood D; EUROASPIRE Investigators (2017) Time trends in lifestyle, risk factor control, and use of evidence-based medications in patients with coronary heart disease in Europe: Results from 3 EUROASPIRE surveys, 1999–2013. Glob Heart 12: 315-322.e3. https://doi.org/10.1016/j.gheart.2015.11.003

Kwon YJ, Kwon GE, Lee HS, Choi MH, Lee JW (2022) The effect of orlistat on sterol metabolism in obese patients. Front Endocrinol (Lausanne) 13: 824269. https://doi.org/10.3389/fendo.2022.824269

Laksana I, Rejeki PS, Herawati L, Al Arif MA, Wardhani IL (2021) High-fat diet increases serum HDL, but not for LDL and HDL/LDL ratio in mice. Folia Med Indonesiana 57: 117–120. https://doi.org/10.20473/fmi.v57i2.16123

Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C; Cholesterol Treatment Trialists' (CTT) Collaborators (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 380: 581–590. https://doi.org/10.1016/S0140-6736(12)60367-5

Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F, 2020. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (eds.). JBI Manual for Evidence Synthesis. JBI. https://doi.org/10.46658/JBIMES-20-08

Morofuji Y, Nakagawa S, Ujifuku K, Fujimoto T, Otsuka K, Niwa M, Tsutsumi K (2022) Beyond lipid-lowering: effects of statins on cardiovascular and cerebrovascular diseases and cancer. Pharmaceuticals 15: 151 https://doi.org/10.3390/ph15020151

Nasri R, Bidel LPR, Rugani N, Perrier V, Carrière F, Dubreucq E, Jay-Allemand C (2019) Inhibition of CpLIP2 lipase hydrolytic activity by four flavonols (galangin, kaempferol, quercetin, myricetin) compared to orlistat and their binding mechanisms studied by quenching of fluorescence. Molecules 24: 2888. https://doi.org/10.3390/molecules24162888

Nikniaz Z, Nikniaz L, Farhangi MA, Mehralizadeh H, Salekzamani S (2023) Effect of orlistat on anthropometrics and metabolic indices in children and adolescents: A systematic review and meta-analysis. BMC Endocr Disord 23: 142. https://doi.org/10.1186/s12902-023-01390-7

Pranoto A, Bagus M, Cahyono A, Yakobus R, Izzatunnisa N, Ramadhan RN, Rejeki PS, Miftahussurur M, Dyah C, Wungu K, Yamaoka Y (2023) Long-term resistance-endurance combined training reduces pro-inflammatory cytokines in young adult females with obesity. Sports 11: 54. https://doi.org/10.3390/sports11030054

Reiner Ž, De Backer G, Fras Z, Kotseva K, Tokgözoglu L, Wood D, De Bacquer D; EUROASPIRE Investigators (2016) Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries - Findings from the EUROASPIRE IV survey. Atherosclerosis 246: 243–250. https://doi.org/10.1016/j.atherosclerosis.2016.01.018

Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA (2012) Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 367: 1891–1900. https://doi.org/10.1056/nejmoa1201832

Sahebkar A, Simental-Mendía LE, Reiner Ž, Kovanen PT, Simental-Mendía M, Bianconi V, Pirro M (2017) Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials. Pharmacol Res 122: 53–65. https://doi.org/10.1016/j.phrs.2017.05.022

Shirai K, Fujita T, Tanaka M, Fujii Y, Shimomasuda M, Sakai S, Samukawa Y (2018) Efficacy and safety of lipase inhibitor orlistat in Japanese with excessive visceral fat accumulation: 24-week, double-blind, randomized, placebo-controlled study. Adv Ther 36: 86–100. https://doi.org/10.6084/m9.figshare.7297526

Sumithran P, Proietto J (2014) Benefit-risk assessment of orlistat in the treatment of obesity. Drug Saf 37: 597–608. https://doi.org/10.1007/s40264-014-0210-7

Tien T, Ardiansyah NR, Sabandar CW, Kardin L, Aritrina P (2023) Inhibition of HMG-CoA reductase activity by kersen leaves (Muntingia calabura L.) to prevent hypercholesterolemia. Galenika J Pharm 9: 102–113. https://doi.org/10.22487/j24428744.2023.v9.i1.16086

Von Hippel PT (2015) The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med Res Methodol 15: 35. https://doi.org/10.1186/s12874-015-0024-z

Werida R, Khairat I, Khedr NF (2021) Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia. Biomed Pharmacother 135: 111179. https://doi.org/10.1016/j.biopha.2020.111179

Zhang L, Zhang S, Yu Y, Jiang H, Ge J (2020a) Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol: A meta-analysis of trials with East Asian populations. Herz 45: 594–602. https://doi.org/10.1007/s00059-018-4767-2

Zhang X, Xing L, Jia X, Pang X, Xiang Q, Zhao X, Ma L, Liu Z, Hu K, Wang Z, Cui Y (2020b) Comparative lipid-lowering/increasing efficacy of 7 statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus: systematic review and network meta-analyses of 50 randomized controlled trials. Cardiovasc Ther 2020: 3987065. https://doi.org/10.1155/2020/3987065

Zhou YH, Ma XQ, Wu C, Lu J, Zhang SS, Guo J, Wu SQ, Ye XF, Xu JF, He J (2012) Effect of anti-obesity drug on cardiovascular risk factors: A systematic review and meta-analysis of randomized controlled trials. PLoS One 7: e39062. https://doi.org/10.1371/journal.pone.0039062

© 2024 Journal of Pharmacy & Pharmacognosy Research

Anti-dormant mycobacterial of marine-derived fungi
J. Pharm. Pharmacogn. Res., vol. 13, no. 1, pp. 16-26, Jan-Feb 2025. DOI: https://doi.org/10.56499/jppres24.1953_13.1.16 Original Article Activity of ethyl acetate extracts of marine-derived fungi against active and hypoxia-induced dormant Mycobacterium [Actividad de extractos de acetato de etilo de hongos de origen marino contra Mycobacterium latente activa e inducida por hipoxia] Muhammad Azhari1, Atik Pereztia Litanjuasari1, … Continue reading Anti-dormant mycobacterial of marine-derived fungi
Rift Valley fever virus RdRp inhibition by RNA polymerase inhibitors
J. Pharm. Pharmacogn. Res., vol. 13, no. 1, pp. 1-15, Jan-Feb 2025. DOI: https://doi.org/10.56499/jppres24.1967_13.1.1 Original Article In silico study of RNA polymerase inhibitor drugs for Rift Valley fever virus using RdRp protein as the target [Estudio in silico de fármacos inhibidores de la ARN polimerasa para el virus de la fiebre del valle del Rift … Continue reading Rift Valley fever virus RdRp inhibition by RNA polymerase inhibitors
Probable interaction between levothyroxine and Thymus vulgaris
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1196-1198, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.2008_12.6.1196 Case Report Probable interaction between levothyroxine sodium and thyme (Thymus vulgaris), about a case report [Interacción probable entre levotiroxina sódica y tomillo (Thymus vulgaris), sobre un reporte de caso] Nassima Elyebdri1,2*, Sihem Baba Ahmed1, Nessrine Abourejal1, Lotfi Loudjedi3, Assia Bououden3, Nour … Continue reading Probable interaction between levothyroxine and Thymus vulgaris

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio